MALT-1

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With Non-Hodgkin Lymphoma and Chronic Lmphocytic Leukemia.
Menu